Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * Treatment of *Helicobacter pylori* infection (in combination with antibiotics). ## Adult Dosing * **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of healing:** 40 mg orally once daily. Lower doses (e.g., 20 mg) may be considered for some patients. * **Pathological hypersecretory conditions:** Start with 40 mg orally or intravenously twice daily. Doses may be increased as clinically indicated, up to 120 mg intravenously or 240 mg orally per day divided into two doses. * ***H. pylori* eradication:** 40 mg orally twice daily for 7-14 days in combination with clarithromycin and amoxicillin, or clarithromycin and metronidazole. ## Pediatric Dosing * **Erosive esophagitis (ages 5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks. * **Erosive esophagitis (ages 1 month to < 5 years):** Dosing is weight-based. * 10 kg to < 20 kg: 10 mg orally once daily. * ≥ 20 kg: 20 mg orally once daily. * Higher doses (e.g., up to 40 mg daily) may be considered based on clinical response and tolerability, but data are limited. ## Dose Adjustments * **Hepatic Impairment:** Maximum dose of 40 mg orally once daily. IV formulation is not recommended. * **Renal Impairment:** No dose adjustment is typically needed. ## Contraindications * Known hypersensitivity to pantoprazole, other benzimidazoles, or any component of the formulation. ## Adverse Effects Common: Diarrhea, headache, dizziness, abdominal pain, nausea, vomiting, flatulence. Long-term use concerns: Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, and potential for fundic gland polyps. ## Key Drug Interactions * **Drugs affected by gastric pH:** PPIs can decrease the absorption of drugs requiring an acidic gastric environment (e.g., ketoconazole, itraconazole, iron salts, vitamin B12). * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May increase concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated; consider alternatives if concerned). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias) with long-term therapy. * Consider vitamin B12 levels with prolonged use (>3 years). * Monitor bone mineral density in patients at risk for osteoporosis. * Assess for *C. difficile* infection if diarrhea develops. ## Clinical Pearls * Administer oral pantoprazole 30-60 minutes before a meal. * For IV administration, reconstitute and dilute according to manufacturer instructions. Do not administer with other medications in the same IV line. * While often dosed for 8 weeks, the need for continued therapy should be reevaluated. * Use the lowest effective dose for the shortest duration necessary to manage the condition. *** **Disclaimer:** This information is intended for healthcare professionals and is a summary. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.